184 related articles for article (PubMed ID: 10540936)
21. Successful implementation of a rural extracorporeal photopheresis program for the treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease in a rural hospital.
Weber LL; Dunbar NM; Meehan KR; Szczepiorkowski ZM; Lansigan F
J Clin Apher; 2015 Dec; 30(6):359-63. PubMed ID: 25691106
[TBL] [Abstract][Full Text] [Related]
22. Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy.
Wilson LD; Licata AL; Braverman IM; Edelson RL; Heald PW; Feldman AM; Kacinski BM
Int J Radiat Oncol Biol Phys; 1995 Jul; 32(4):987-95. PubMed ID: 7607973
[TBL] [Abstract][Full Text] [Related]
23. [The application of photopheresis in the therapy of cancerous and autoimmune diseases].
Dall'Amico R; Zacchello G; Heald P
Recenti Prog Med; 1991 May; 82(5):294-9. PubMed ID: 1887157
[TBL] [Abstract][Full Text] [Related]
24. ECP versus PUVA for the treatment of cutaneous T-cell lymphoma.
Geskin L
Skin Therapy Lett; 2007 Jun; 12(5):1-4. PubMed ID: 17609808
[TBL] [Abstract][Full Text] [Related]
25. Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017-2019.
Girardi M; Carlson K; Huang X; Corman SL; Edmundson P; Schmier J; Kale HP; Raina R; Foss F
J Dermatolog Treat; 2024 Dec; 35(1):2360568. PubMed ID: 38852942
[TBL] [Abstract][Full Text] [Related]
26. Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis.
Knobler R; Duvic M; Querfeld C; Straus D; Horwitz S; Zain J; Foss F; Kuzel T; Campbell K; Geskin L
Photodermatol Photoimmunol Photomed; 2012 Oct; 28(5):250-7. PubMed ID: 22971190
[TBL] [Abstract][Full Text] [Related]
27. Cost-Effectiveness of Extracorporeal Photopheresis for the Treatment of Patients With Erythrodermic (Stage T
Peacock A; Dehle F; Mesa Zapata OA; Prince HM; Gennari F; Taylor C
Value Health; 2022 Jun; 25(6):965-974. PubMed ID: 35667784
[TBL] [Abstract][Full Text] [Related]
28. Management of cutaneous T-Cell lymphoma patients with extracorporeal photopheresis. The Hellenic experience.
Siakantaris MP; Tsirigotis P; Stavroyianni N; Argyropoulos KV; Girkas K; Pappa V; Chondropoulos S; Papadavid E; Sakellari I; Anagnostopoulos A; Antoniou C; Dervenoulas J
Transfus Apher Sci; 2012 Apr; 46(2):189-93. PubMed ID: 22178592
[TBL] [Abstract][Full Text] [Related]
29. Serum soluble interleukin 2 receptor levels in erythrodermic cutaneous T-cell lymphoma correlate with response to photopheresis-based treatment.
Goldman BD; Oh SK; Davis BE; Kadin ME; Poiesz BJ; Koh HK
Arch Dermatol; 1993 Sep; 129(9):1166-70. PubMed ID: 8363402
[TBL] [Abstract][Full Text] [Related]
30. Extracorporeal photopheresis: what is it and when should it be used?
Scarisbrick J
Clin Exp Dermatol; 2009 Oct; 34(7):757-60. PubMed ID: 19663836
[TBL] [Abstract][Full Text] [Related]
31. Treatment of advanced mycosis fungoides/Sézary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy.
Quaglino P; Fierro MT; Rossotto GL; Savoia P; Bernengo MG
Br J Dermatol; 2004 Feb; 150(2):327-36. PubMed ID: 14996105
[TBL] [Abstract][Full Text] [Related]
32. Evidence-based practice of photopheresis 1987-2001: a report of a workshop of the British Photodermatology Group and the U.K. Skin Lymphoma Group.
McKenna KE; Whittaker S; Rhodes LE; Taylor P; Lloyd J; Ibbotson S; Russell-Jones R; ;
Br J Dermatol; 2006 Jan; 154(1):7-20. PubMed ID: 16403088
[TBL] [Abstract][Full Text] [Related]
33. U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease.
Scarisbrick JJ; Taylor P; Holtick U; Makar Y; Douglas K; Berlin G; Juvonen E; Marshall S;
Br J Dermatol; 2008 Apr; 158(4):659-78. PubMed ID: 18241274
[TBL] [Abstract][Full Text] [Related]
34. Reciprocal modulation of circulating CD4+CD25+bright T cells induced by extracorporeal photochemotherapy in cutaneous T-cell lymphoma and chronic graft-versus-host-disease patients.
Quaglino P; Comessatti A; Ponti R; Peroni A; Mola F; Fierro MT; Savoia P; Novelli M; Bernengo MG
Int J Immunopathol Pharmacol; 2009; 22(2):353-62. PubMed ID: 19505389
[TBL] [Abstract][Full Text] [Related]
35. Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides.
Wilson LD; Jones GW; Kim D; Rosenthal D; Christensen IR; Edelson RL; Heald PW; Kacinski BM
J Am Acad Dermatol; 2000 Jul; 43(1 Pt 1):54-60. PubMed ID: 10863224
[TBL] [Abstract][Full Text] [Related]
36. Photopheresis in the treatment of cutaneous T-cell lymphoma: current status.
Zic JA
Curr Opin Oncol; 2012 Jan; 24 Suppl 1():S1-10. PubMed ID: 22157241
[TBL] [Abstract][Full Text] [Related]
37. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
[TBL] [Abstract][Full Text] [Related]
38. An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphoma.
Geskin L; Malone DC
J Dermatolog Treat; 2018 Aug; 29(5):522-530. PubMed ID: 29191068
[TBL] [Abstract][Full Text] [Related]
39. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.
Zic JA
Dermatol Clin; 2015 Oct; 33(4):765-76. PubMed ID: 26433848
[TBL] [Abstract][Full Text] [Related]
40. Circulating CD4+CD7- lymphocyte burden and rapidity of response: predictors of outcome in the treatment of Sézary syndrome and erythrodermic mycosis fungoides with extracorporeal photopheresis.
Stevens SR; Baron ED; Masten S; Cooper KD
Arch Dermatol; 2002 Oct; 138(10):1347-50. PubMed ID: 12374541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
